Amneal Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Amneal Pharmaceuticals (AMRX) Misses Q3 EPS by 10c, Lowers FY EPS Guidance
November 6, 2019 6:43 AM ESTAmneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.04, $0.10 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $378.3 million versus the consensus estimate of $408.98 million.
GUIDANCE:
Amneal Pharmaceuticals sees FY2019 EPS of $0.31, versus the consensus of... More
